Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations
- PMID: 8405020
- DOI: 10.1007/BF02440867
Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations
Abstract
We have investigated the prevalence of poor metabolisers (PM) of S-mephenytoin in 373 unrelated, healthy Spanish Caucasian subjects, based on the enantiomeric S/R mephenytoin ratio in urine collected 0-8 h and 24-32 h after intake of the racemic drug. Five of the subjects were PM (1.34%, 95% confidence interval 0.18-2.59%), a prevalence lower than in 6 other Caucasian populations, but only significantly lower than in studies in France and Switzerland (P < 0.01). We suggest that this difference might be due to the use of different phenotyping procedures.
Similar articles
-
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.Clin Pharmacol Ther. 1984 Dec;36(6):773-80. doi: 10.1038/clpt.1984.256. Clin Pharmacol Ther. 1984. PMID: 6499356
-
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.Clin Pharmacol Ther. 1985 Oct;38(4):402-8. doi: 10.1038/clpt.1985.194. Clin Pharmacol Ther. 1985. PMID: 4042523
-
Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.Pharmacol Toxicol. 1993 Jul;73(1):46-8. doi: 10.1111/j.1600-0773.1993.tb01956.x. Pharmacol Toxicol. 1993. PMID: 8234192
-
Genetic polymorphism of S-mephenytoin 4'-hydroxylation.Psychopharmacol Bull. 1996;32(2):219-30. Psychopharmacol Bull. 1996. PMID: 8783891 Review.
-
Polymorphism in stereoselective hydroxylations of mephenytoin and hexobarbital by Japanese liver samples in relation to cytochrome P-450 human-2 (IIC9).Xenobiotica. 1992 Sep-Oct;22(9-10):1083-92. doi: 10.3109/00498259209051862. Xenobiotica. 1992. PMID: 1441599 Review.
Cited by
-
Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.Eur J Drug Metab Pharmacokinet. 1996 Apr-Jun;21(2):129-38. doi: 10.1007/BF03190261. Eur J Drug Metab Pharmacokinet. 1996. PMID: 8839686 Review.
-
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.Clin Pharmacokinet. 2002;41(12):913-58. doi: 10.2165/00003088-200241120-00002. Clin Pharmacokinet. 2002. PMID: 12222994 Review.
-
Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.Pharmacogenomics J. 2016 Apr;16(2):113-23. doi: 10.1038/tpj.2015.70. Epub 2015 Oct 27. Pharmacogenomics J. 2016. PMID: 26503820 Review.
-
Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.Br J Clin Pharmacol. 1999 Sep;48(3):402-8. doi: 10.1046/j.1365-2125.1999.00009.x. Br J Clin Pharmacol. 1999. PMID: 10510153 Free PMC article.
-
Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.Br J Clin Pharmacol. 1999 Aug;48(2):158-67. doi: 10.1046/j.1365-2125.1999.00005.x. Br J Clin Pharmacol. 1999. PMID: 10417492 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials